Phase 3 PRABITAS trial backs 14-day trifluridine–tipiracil plus bevacizumab schedule
Start here
The pragmatic, multicentre, open-label, randomised phase 3 non-inferiority PRABITAS trial, conducted in Japan, tested a 14-day schedule of trifluridine–tipiracil plus bevacizumab against the standard 28-day schedule in refractory metastatic colorectal cancer. The trial found the 14-day schedule non-inferior to the 28-day schedule for overall survival, with lower haematological and gastrointestinal toxicity. On the strength of these results, the simplified schedule is supported as a new standard for this combination. How quickly the finding changes practice outside Japan, and whether other trifluridine-based regimens adopt the schedule, are still open questions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.comPick[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
The phase 3 PRABITAS trial showed that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the 28-day schedule for overall survival. The study was conducted in refractory metastatic colorectal cancer, and the 14-day schedule had lower haematological and gastrointestinal toxicity. The results support the simplified schedule as a new standard for this combination.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 24 21:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.